Introduction to Nasal Spray Vaccination in Australia
For the first time, some Australians can now choose a nasal spray vaccination as an alternative to the traditional injection against influenza. This development comes as Australia faces a surge in influenza cases driven by the highly contagious Super-K strain. Health experts are urging Aussies to get vaccinated against this fast-spreading variant, with more than 25,000 cases recorded so far.
The Availability of FluMist
Currently, all vaccines used in Australia are administered via injection. However, children and teens aged from two to 17 years old can now opt for a needle-free option: FluMist, a nasal spray vaccination. This vaccine is widely used in the United Kingdom, Europe, Canada, and the United States.
According to Queensland’s chief health officer, Dr Marianne Gale, there is “extensive evidence” from overseas that supports FluMist as an effective alternative to the traditional vaccine. The spray uses a weakened form of the influenza virus to stimulate an immune response. While it may cause minor side effects such as a runny nose, sore throat, and fever, these are typically short-lived.
Safety and Effectiveness of FluMist
“The nasal spray vaccine has been used for decades in the northern hemisphere, very widely and in millions of children, and it has been used safely and demonstrated equivalent effectiveness,” she said. Health authorities hope that the availability of FluMist will help boost vaccination rates and reduce the spread of influenza.
According to the National Centre for Immunisation Research and Surveillance Australia, influenza vaccination for children aged six months to five years of age has been on a decline. In 2020, more than 44 per cent of children in this age group had received the flu vaccine. However, this figure fell by 19 per cent in 2025.
Availability Across Australian States
As of early April, FluMist is now available for free across four Australian states. Australia’s medicine regulators, the Therapeutic Goods Administration, have approved FluMist with a conditional age range. In Queensland and South Australia, it is available for those aged two to five (inclusive). In New South Wales, it is available for those aged two to four years (inclusive), while in Western Australia, it is available for those aged two to 11 years (inclusive).
In the ACT, Victoria, Tasmania, and the Northern Territory, FluMist is only accessible through the private market. General practitioners have urged all states and cities to include nasal spray in their free flu vaccination programs to ensure broader access and higher vaccination rates.
Benefits of Nasal Spray Vaccination
The introduction of FluMist offers several benefits. It provides a non-invasive option for children who may be afraid of needles, potentially increasing the number of children receiving the vaccine. Additionally, the nasal spray may offer better protection against certain strains of the flu, particularly in younger populations.
Health officials believe that making FluMist more widely available could significantly impact public health outcomes. By reducing the number of flu cases, especially among vulnerable groups like children and the elderly, the overall burden on the healthcare system could be lessened.
Future Prospects
With the approval of FluMist and its availability in select regions, there is potential for expansion in the future. As more data becomes available on its long-term effectiveness and safety, other states may follow suit in offering the nasal spray as part of their free vaccination programs.
The success of FluMist in other countries provides a strong foundation for its implementation in Australia. Continued research and monitoring will be essential to ensure that the vaccine remains a safe and effective option for the population.
Conclusion
The availability of FluMist marks a significant step forward in Australia’s approach to influenza prevention. By offering a needle-free alternative, health authorities aim to increase vaccination rates and protect more people from the flu. As the country continues to navigate the challenges posed by the Super-K strain, the introduction of FluMist could play a crucial role in mitigating the spread of the virus.
